Atypical Endometrial Hyperplasia Clinical Trials

9 recruiting

Atypical Endometrial Hyperplasia Trials at a Glance

11 actively recruiting trials for atypical endometrial hyperplasia are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Beijing, Shanghai, and Shanghai. Lead sponsors running atypical endometrial hyperplasia studies include Xiaojun Chen, Peking University People's Hospital, and Mayo Clinic.

Browse atypical endometrial hyperplasia trials by phase

Treatments under study

About Atypical Endometrial Hyperplasia Clinical Trials

Looking for clinical trials for Atypical Endometrial Hyperplasia? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Atypical Endometrial Hyperplasia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Atypical Endometrial Hyperplasia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Ovarian CancerCervical CancerEndometrial Cancer+3 more
Mayo Clinic3,110 enrolled24 locationsNCT05051722
Recruiting

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Endometrial CancerEndometrial Intraepithelial NeoplasiaAtypical Endometrial Hyperplasia+2 more
Exact Sciences Corporation4,200 enrolled1 locationNCT07544680
Recruiting
Phase 2

Intrauterine Injection of Type III Collage in FST of EC/AEH

Endometrial CancerAtypical Endometrial Hyperplasia
Wang Jianliu30 enrolled1 locationNCT07377734
Recruiting

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons

Ovarian CancerEndometrial CancerEndometrial Cancer Precursors+1 more
University of Alabama at Birmingham1,500 enrolled1 locationNCT03538665
Recruiting
Phase 2Phase 3

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone Resistance
Xiaojun Chen80 enrolled2 locationsNCT05316935
Recruiting
Phase 2Phase 3

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

ObesityEndometrial NeoplasmsAtypical Endometrial Hyperplasia+1 more
Xiaojun Chen29 enrolled2 locationsNCT06379113
Recruiting
Phase 2Phase 3

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Overweight and ObesityAtypical Endometrial HyperplasiaFertility Issues
Xiaojun Chen172 enrolled1 locationNCT05316493
Recruiting

Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer

Atypical Endometrial HyperplasiaEndometrial Carcinoma Stage I
Peking University People's Hospital244 enrolled1 locationNCT05647109
Recruiting
Phase 2

Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I
Peking University People's Hospital38 enrolled1 locationNCT06102863
Recruiting
Phase 2

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Atypical Endometrial HyperplasiaEndometrial Carcinoma Stage I
Peking University People's Hospital82 enrolled1 locationNCT05675787
Recruiting
Phase 2Phase 3

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Endometrial CancerAtypical Endometrial Hyperplasia
West China Second University Hospital224 enrolled1 locationNCT03463252